Literature DB >> 2426639

Antenatal diagnosis and palliative treatment of nonimmune hydrops fetalis secondary to pulmonary extralobar sequestration.

C Weiner, M Varner, K Pringle, H Hein, R Williamson, W L Smith.   

Abstract

The causes of nonimmune hydrops fetalis are multiple. Despite the fact that many of the affected fetuses are otherwise free of fatal abnormalities, many die in the neonatal period from pulmonary hypoplasia. The overall perinatal mortality is as high as 80%. Extralobar pulmonary sequestration is an abnormal and nonaerated mass of extra pulmonary-located lung tissue supplied by a systemic artery, and is a rare cause of nonimmune hydrops. In the only two published reports, the hydropic fetuses died at birth. Both the first antenatal diagnosis of this disorder and the first attempt at palliative in utero therapy are reported herein. Though the fetus ultimately delivered prematurely and succumbed, treatment was associated with both subjective improvements in fetal well-being and objective reversal of the hydrops.

Entities:  

Mesh:

Year:  1986        PMID: 2426639

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

1.  Pre- and postnatal treatment of a pulmonary sequestration presenting as a unilateral hydrothorax.

Authors:  A Rajimwale; D L Byrne; G P Taylor; D Grier; R D Spicer
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

2.  Pulmonary sequestrations detected by antenatal ultrasound.

Authors:  J A Crameri; W D Ford; M E Furness
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

Review 3.  Congenital cystic lung disease: contemporary antenatal and postnatal management.

Authors:  Richard G Azizkhan; Timothy M Crombleholme
Journal:  Pediatr Surg Int       Date:  2008-04-05       Impact factor: 1.827

4.  Management Options for Fetal Bronchopulmonary Sequestration.

Authors:  Magdalena Litwinska; Ewelina Litwinska; Krzysztof Szaflik; Marzena Debska; Tomasz Szajner; Katarzyna Janiak; Piotr Kaczmarek; Miroslaw Wielgos
Journal:  J Clin Med       Date:  2022-03-20       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.